<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="26856">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02062515</url>
  </required_header>
  <id_info>
    <org_study_id>BD-IC-IV51</org_study_id>
    <nct_id>NCT02062515</nct_id>
  </id_info>
  <brief_title>Icotinb in Advanced Non-small Cell Lung Cancer (NSCLC) With Hepatic Insufficiency</brief_title>
  <official_title>Safety Assessment of Icotinb in Advanced NSCLC Patients With Hepatic Insufficiency: A Multi-center, Open-label, Single-arm Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Betta Pharmaceuticals Co.,Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Betta Pharmaceuticals Co.,Ltd.</source>
  <oversight_info>
    <authority>China: Food and Drug Administration</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether Icotinib is efficient and safe in
      treating advanced non-small cell lung cancer (NSCLC) patients with hepatic insufficiency.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients with hepatic insufficiency is an important subgroup of who receive EGFR TKIs.
      Phase I/II studies showed that Icotinib has good security. Based on the above
      considerations, this single-arm, open-label study is designed to evaluate the safety of
      icotinib 125mg three times daily for histologically or cytologically confirmed NSCLC
      patients with hepatic insufficiency.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>February 2014</start_date>
  <completion_date type="Anticipated">May 2015</completion_date>
  <primary_completion_date type="Anticipated">February 2015</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Number of Participants with Adverse Events</measure>
    <time_frame>Up to 4 weeks</time_frame>
    <safety_issue>Yes</safety_issue>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Non-small Cell Lung Cancer</condition>
  <arm_group>
    <arm_group_label>Icotinib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Icotinib is administered orally 125 mg three times per day continuously for four weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>icotinib</intervention_name>
    <description>Icotinib is administered orally 125 mg three times per day continuously for four weeks</description>
    <arm_group_label>Icotinib</arm_group_label>
    <other_name>BPI-2009</other_name>
    <other_name>Commana</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histologically or cytologically confirmed diagnosis of IIIB/IV stage NSCLC patients
             who are not suitable for surgery or radiotherapy

          -  ECOG performance status points (PS) is 0-2

          -  Liver function:

        A (mild hepatic dysfunction):

        A1)  total bilirubin within normal limit (ULN), while AST&gt; ULN;

        A2)  total bilirubin within1.0-1 .5 × ULN;

        B (moderate hepatic dysfunction): total bilirubin within1.5-3 .0 × ULN

          -  No malabsorption or other gastrointestinal disorders effecting drug absorption

          -  Life expectancy: more than 12 weeks.

        Exclusion Criteria:

          -  Previous usage of  HER/EGFR inhibitors or other target molecule drugs ( small
             molecule drugs or monoclonal antibody therapy )

          -  Patients requires liver shunt , stent placement, or radiotherapy when 2 weeks before
             the start of the study or research process .

          -  Patients with active hepatitis and cirrhosis.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hao Long, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Sun Yat-sen Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Sun Yat-sen Cancer Center</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510060</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>February 2014</verification_date>
  <lastchanged_date>February 12, 2014</lastchanged_date>
  <firstreceived_date>February 12, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Hepatic Insufficiency</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
